When MDMA appears in a toxicology result, one of the first questions is whether the measured concentration reflects dose alone. It does not. Drug metabolism, sampling time, co-administered medications, and genetic phenotype can all change the concentration-time profile. A controlled study of MDMA and bupropion illustrates how one metabolic pathway can matter without becoming a complete explanation.
Steuer and colleagues studied the stereoselective pharmacokinetics of MDMA in 16 healthy participants. Thirteen were classified as CYP2D6 extensive metabolizers and three as intermediate metabolizers. In a double-blind crossover design, participants received a week of placebo or bupropion pretreatment before a 125 mg MDMA dose or placebo.
This design mattered because bupropion inhibits CYP2D6. The investigators could therefore compare ordinary metabolism with experimentally reduced CYP2D6 activity while separately measuring the R- and S-enantiomers of MDMA and several metabolites.
Bupropion increased peak concentration and 24-hour exposure for both MDMA enantiomers. For R-MDMA, the reported increases were about 9% for peak concentration and 25% for area under the curve. For S-MDMA, the increases were about 16% and 38%, respectively. Several CYP2D6-dependent sulfate and glucuronide metabolites fell by roughly 40%.
The three intermediate metabolizers showed pharmacokinetic patterns similar to extensive metabolizers after bupropion pretreatment. That observation supports the biological role of CYP2D6, but the very small intermediate-metabolizer subgroup prevents broad numerical generalization.
MDMA is administered as a racemic mixture, but its enantiomers are not processed identically. Measuring them separately can reveal pathway-specific effects that a single total-MDMA number hides. In this experiment, CYP2D6 inhibition altered stereoselective exposure, although the authors considered the change in stereoselectivity unlikely to be clinically important.
The study supports a restrained interpretation: CYP2D6 inhibition can raise MDMA exposure and suppress particular metabolite pathways. It does not supply a universal correction factor for a case result. The experiment involved a known oral dose, controlled timing, healthy volunteers, and a specific inhibitor. Casework may involve unknown dose, repeated dosing, variable tablet content, other substances, illness, delayed collection, or postmortem change.
A higher concentration therefore should not automatically be attributed to a higher dose, and a concentration that appears ordinary does not rule out impairment or toxicity. Medication history and CYP2D6 phenotype may be relevant, but neither substitutes for the complete timeline and clinical or behavioral evidence.
The study is most useful as evidence that metabolism can shift exposure in a measurable way. It is not evidence that a single blood value reveals dose, timing, impairment, or cause of death by itself.
Steuer AE et al. “Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.” PLoS One (2016). PubMed PMID 26967321; DOI 10.1371/journal.pone.0150955.